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A cute myocardial infarction (AMI) is associated with an acute-phase inflammatory reaction mea- TABLE I Patient Characteristics 
surable by determination of serum C-reactive pro- 
tein.l-5 The highest serum C-reactive protein values 
correlate with the size of the AM1 when thrombolytic 
treatment is not given.3 If reperfusion by thrombolytic 
treatment occurs in AMI, the serum C-reactive protein 
values are lower than would be expected according to 
infarct size.“-5 These low serum C-reactive protein 
values are associated with a favorable survival prog- 
nosis during the first 6 months after AML6 In this 
study we investigate the infarct-related acute-phase 
reaction after treatment with accelerated alteplase, 
streptokinase, or a combination of both. We also 
wanted to elucidate whether the Thrombolysis in 
Myocardial Infarction (TIMI) patency grade of the 
infarct-related artery7 was associated with this acute- 
phase reaction. 
Combined 
Alteplase- 
Alteplose Streptokinase Streptokinase 
(n = 48) (n = 63) (n = 32) 
Age (yr + SD) 592 12 61 -+ 12 60 k 11 
Women (%) 9 (18%) 19 (30%) 3 (9%) 
Time from chest pain 3.5 i- 1.9 3.5 i- 2.2 3.5 t 4.7 
onset to start of 
thrombolysis (hours 
+ SD) 
Time from the beginning 96 i 9 972 10 97 k 9 
of the treatment to 
angiography (minute 
k SD) 
Infarct location (%) 
Anterior 24 (50%) 23 (37%) 21 (66%) 
Inferior 22 (46%) 35 (55%) 10 (31%) 
Other 2 (4%) 5 (8%) 1 (3%) 
. . . 
We studied patients who had been randomized to 
undergo early (90 minute) coronary angiography in 
the Global Utilization of Streptokinase and TPA (al- 
teplase) for Occluded Coronary Arteries (GUSTO-I) 
enzyme substudy. Overall, 174 patients from the 553 
patients in the enzyme substudy had been randomly 
assigned to angiography at the centers that also par- 
ticipated in the GUSTO-I angiographic substudy. Be- 
cause the GUSTO-I main triallo was unable to show 
any survival difference between the 2 streptokinase 
monotherapies, we chose to combine these groups. 
Accordingly, in this study we compared 3 treatment 
groups: (1) the accelerated alteplase group, (2) the 
streptokinase groups, and (3) the combination treat- 
ment group. 
tyrate dehydrogenase as described. l I,‘2 The size of the 
AM1 was determined from the cumulative release of 
hydroxybutyrate lactate dehydrogenase.12 In 143 of 
the patients all 11 blood samples were available for 
analysis. In 3 patients the highest serum C-reactive 
protein could not be determined with certainty be- 
cause of death within the first 2 days. These 3 patients 
were all in the streptokinase group and are not in- 
cluded in the final analyses. 
Coronary angiography was performed in all pa- 
tients 90 minutes after the start of the thrombolytic 
therapy. The angiographic patency of the infarct-re- 
lated coronary artery was graded from 0 to 3 using the 
TIMI classifications.7 
Blood samples were available from 146 patients, 
48 of whom had been treated with alteplase, 66 with 
streptokinase, and 32 with the combination of strep- 
tokinase and alteplase. Blood samples for the study 
were drawn at the start of thrombolytic treatment and 
1, 3,5, 12, l&24, 36,48,72, and 96 hours later. They 
were analyzed for C-reactive protein and hydroxybu- 
Continuous variables were summarized in terms of 
means + SD and categorical variables by percentages. 
Multivariate analysis, the Student’s t test and chi- 
square test were used in statistical analyses. These 
were determined with the Statgraphics Plus for Win- 
dows (Version 2.0; Manugistics Inc., Rockville, 
Maryland) statistical package. 
. . . 
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At randomization the patients in alteplase, strep- 
tokinase, and alteplase and streptokinase treatment 
groups did not differ with respect to age, delay from 
the onset of chest pain to the start of the treatment, 
time from the beginning of the treatment to angiogra- 
phy, or infarct location (Table I). 
Highest serum C-reactive protein concentrations 
were reached 36 to 96 hours after AMI. The serum 
C-reactive protein concentrations were lower overall in 
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FIGURE 1. Serum C-reactive protein concentration after myocardial infarction in dif- 
ferent treatment grou 
infarction (means an B 
s. A, serum C-reactive protein as a function of time after the 
95% confidence intervals for the means). 6, highest serum C- 
reactive protein concentrations [means and 95% confidence intervals for the means). 
The existence of significant differences between the groups was discovered by the 
analysis of variance method; significant differences were restudied by Student’s t test 
to obtain the exact p values. 
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FIGURE 2. Highest serum C-reactive protein concentrations in 
patients with TtMI grade 0 to 2 and TIMI grade 3 blood flow in 
the infarct-related coronary artery (means and 95% confidence 
intervals of the means). The statistical significance was calculated 
by Student’s t test. Open bar, TIMI 0 to 2 flow in the infarct-re- 
lated coronary artery. Lined bar, TJMI 3 flow in the infarct-re- 
lated coronary artery. 
the alteplase group than in the streptokinase and combi- 
nation treatment groups, as were the peak serum concen- 
trations (Figure 1). There was a tendency toward smaller 
infarcts in the alteplase-treated patients than in the strep- 
tokinase-treated patients, but the dif- 
ference was not statistically signifi- 
cant. The cumulative amounts of hy- 
droxybutyrate dehydrogenase released 
were 4.51 ? 3.17, 5.61 + 3.56, and 
4.47 ? 3.92 g-l%@ in the alteplase, 
streptokinase, and combination treat- 
ment groups, respectively. 
The peak C-reactive protein values 
were lower in patients who had TIMI 
grade 3 perfusion in the infarct-related 
coronary artery than in those with 
TIMI grade 0 to 2 flow (Figure 2). 
When the patients who had TIM1 
grade 0 to 2 flow were further divided 
into grade 2 versus grade 0 to 1 flow, 
the peak C-reactive protein values did 
not differ between these groups (82 ? 
67 and 75 + 58 mg/L,). According to 
multivariate analysis, the peak C-reac- 
tive protein values of the patients who 
had TIMI grade 3 flow differed signif- 
icantly (p = 0.020) from those of pa- 
tients who had TIM1 grade 2 flow, 
whereas the difference between pa- 
tients who had grade 2 flow versus 
grade 0 to 1 flow did not quite reach 
statistical significance (p = 0.074). Pa- 
tients who had TIMI grade 3 flow had smaller enzyme 
release than those who had grade 0 to 2 flow (4.0 + 3.2 
and 5.6 + 3.7 g-EqlL hydroxybutyrate dehydrogenase 
released; p = 0.008). 
Among patients who died during hospitalization for 
whom a reliable peak serum C-reactive protein concen- 
tration could be determined, values were higher among 
those who survived (143 2 122 vs 70 ? 54 mg/L; p 
cO.01). There were only 8 deaths in the study, however, 
and in only 5 of these patients was a reliable peak value 
of serum C-reactive protein available. 
. . . 
This study shows that treatment of AM1 with ac- 
celerated dosing of alteplase leads to a smaller acute- 
phase reaction than does streptokinase treatment alone 
or combination treatment with streptokinase and alte- 
plase. In the GUSTO-I enzyme substudy, Baardman et 
al* showed that treatment with alteplase led to smaller 
infarcts, as determined from the release of hydroxy- 
butyrate dehydrogenase, than did treatment with strep- 
tokinase. In the present subset of their patients, there 
was only a trend toward smaller infarcts in the alte- 
plase-treated patients compared with other patients. A 
smaller sample size.probably explains why we could 
not detect a significant difference. This finding is 
further supported by our finding that, in accordance 
with the main study, there was a significant associa- 
tion between infarct size and the TIM1 flow grade in 
the infarct-related artery. However, our earlier stud- 
ies3z5 have shown that in patients who undergo throm- 
bolysis for myocardial infarction, the patency of the 
infarct-related artery affects the serum C-reactive pro- 
tein values independent of its effect on infarct size. In 
this study, the lower peak C-reactive protein values 
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were significantly associated with complete reperfu- 
sion (TIM1 grade 3 flow) in the infarct-related coro- 
nary artery. It thus seems that the better early patency 
of the infarct-related artery obtained with alteplase 
compared with streptokinase or the combination treat- 
ment’3 reduces the associated acute-phase reaction. 
It has been shown that the patients with TIM1 grade 
3 flow in the infarct-related artery have a favorable 
survival prognosis. 13,i4 We have shown that patients 
who undergo thrombolysis for AM1 and whose serum 
C-reactive protein values remain low have a decreased 
risk of death than those whose values increase over 
time.6 We did not specifically examine the relation of 
the peak serum C-reactive protein value and early 
mortality in this study; nevertheless, patients who died 
during hospitalization and in whom the peak serum 
C-reactive protein value could be reliably determined 
had higher values than those who survived. 
In conclusion, thrombolytic treatment of AM1 
with accelerated alteplase is associated with lower 
peak serum C-reactive protein values than treat- 
ment with either streptokinase or a combination of 
streptokinase and alteplase. The low-peak serum 
C-reactive protein values were associated with 
complete reperfusion of the infarct-related coro- 
nary artery. Thus, the more efficient reperfusion 
with alteplase compared with the other regimensI 
may reduce the inflammatory reaction of AMI. 
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Clinical and Angiographic Implications of Balloon 
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C oronary stenting is increasingly being used during percutaneous coronary interventions. 1-3 This tech- 
nique is currently selected not only for patients with 
suboptimal results or complications after balloon di- 
lation, but also electively, in an attempt to reduce the 
restenosis rate.‘,* In the early days, coronary stenting 
was flawed by a relatively high incidence of subacute 
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stent thrombosis and the requirement for prolonged 
anticoagulation, with its associated bleeding compli- 
cations.’ Today, these 2 important limitations have 
been mostly overcome by improvements in stent im- 
plantation techniques. 3 Intravascular ultrasound stud- 
ies frequently demonstrate inadequate stent deploy- 
ment (incomplete expansion, suboptimal apposition, 
or stent asymmetry) even in patients with excellent 
angiographic results, and that high inflation pressures 
may help to optimize the implantation of these de- 
vices.3 This new strategy, namely, using relatively 
high pressures in conjunction with a simple regimen 
of antiplatelet therapy, has been associated with ex- 
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